Table 4.
Associations between blood cytokine levels and patient characteristics.
| sCD40L | CCL5 | VEGF | G-CSF | NLR | IL-17F | IP-10 | TNF-RI | IFN-γ | Gran-zyme A | TNF | IL-12p70 | IL-2 | IL-4 | IL-1β | ICAM- 1 | Angio-genin | IL-6 | IL-5 | IL-10 | IL-8 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sex (m/w) | FC=0.8 p=0.06 |
FC=0.9 p=0.20 |
FC=1.1 p=0.13 |
FC=3 p=0.49 |
FC=1.2 p=0.24 |
FC>10 p=0.11 |
FC=1.1 p=0.91 |
FC=1.1 p=0.14 |
FC>10 p=0.25 |
FC=2 p=0.29 |
FC=8 p=0.70 |
FC=10 p=0.98 |
FC=69 p=0.94 |
FC=143 p=0.89 |
FC=13 p=0.37 |
FC=4 p=0.78 |
FC=0.5 p=0.76 |
FC=4 p=0.003 |
FC=22 p=0.78 |
FC=11 p=0.75 |
FC=3 p=0.11 |
| age | r=-0.25 p=0.002 |
r=-0.21 p=0.009 |
r=-0.01 p=0.884 |
r=-0.13 p=0.11 |
r=-0.11 p=0.11 |
r=0.10 p=0.202 |
r=0.32 p=4x10-5 |
r=0.18 p=0.029 |
r=0.07 p=0.487 |
r=0.12 p=0.124 |
r=0.01 p=0.931 |
r=0.08 p=0.393 |
r=0.01 p=0.956 |
r=-0.02 p=0.82 |
r=-0.19 p=0.035 |
r=0.153 p=0.058 |
r=-0.01 p=0.884 |
r=0.13 p=0.12 |
r=0.09 p=0.365 |
r=0.01 p=0.97 |
r=0.08 p=0.341 |
|
smokers/
non-smokers |
FC=0.9 p=0.71 |
FC=0.9 p=0.41 |
FC=1.8 p=0.03 |
FC=3 p=0.39 |
FC=1.1 p=0.70 |
FC=6 p=0.43 |
FC=1.0 p=0.16 |
FC=0.8 p=0.40 |
FC>10 p=0.57 |
FC=1.7 p=0.64 |
FC=98 p=0.48 |
FC=45 p=0.22 |
FC>10 p=0.11 |
FC=530 p=0.81 |
FC=196 p=0.75 |
FC=2 p=0.64 |
FC=1.6 p=0.42 |
FC=1.6 p=0.99 |
FC=18 p=0.55 |
FC=9 p=0.29 |
FC=1.9 p=0.50 |
|
CMV
pos/neg |
FC=1.1 p=0.54 |
FC=0.98 p=0.45 |
FC=0.8 p=0.79 |
FC=0.2 p=0.46 |
FC=1 p=0.25 |
FC<0.1 p=0.16 |
FC=1.3 p=0.47 |
FC=1.3 p=0.75 |
FC<0.1 p=0.17 |
FC=0.5 p=0.59 |
FC=0.1 p=0.38 |
FC=0.1 p=0.40 |
FC<0.1 p=0.81 |
FC=0.1 p=0.73 |
FC<0.1 p=0.26 |
FC=5 p=0.61 |
FC=0.9 p=0.72 |
FC=0.8 p=0.59 |
FC<0.1 p=0.19 |
FC<0.1 p=0.85 |
FC=0.5 p=0.59 |
|
PD-L1 TPS
(50+/1-49/0) |
r=-0.03 p=0.68 |
r=-0.20 p=0.014 |
r=0.109 p=0.178 |
r=-0.11 p=0.16 |
r=-0.13 p=0.11 |
r=0.4 p=0.65 |
r=0.26 p=0.001 |
r=-0.04 p=0.59 |
r=0.07 p=0.44 |
r=0.10 p=0.20 |
r=0.08 p=0.38 |
r=0.07 p=0.47 |
r=0.06 p=0.53 |
r=0.13 p=0.18 |
r=0.06 p=0.55 |
r=-0.19 p=0.02 |
r=0.03 p=0.67 |
r=0.25 p=0.002 |
r=-0.08 p=0.42 |
r=0.05 p=0.60 |
r=0.05 p=0.51 |
|
No. of meta-
static sites |
r=-0.01 p=0.91 |
r=-0.11 p=0.19 |
r=0.13 p=0.15 |
r=-0.05 p=0.59 |
r=0.07 p=0.41 |
r=0.04 p=0.69 |
r=0.04 p=0.63 |
r=0.23 p=0.006 |
r=0.05 p=0.62 |
r=0.04 p=0.66 |
r=0.06 p=0.53 |
r=-0.01 p=0.92 |
r=-0.02 p=0.83 |
r=0.08 p=0.42 |
r=-0.05 p=0.60 |
r=0.06 p=0.51 |
r=0.03 p=0.73 |
r=0.23 p=0.007 |
r=-0.12 p=0.23 |
r=0.07 p=0.47 |
r=0.20 p=0.02 |
Weak, but significant correlations (|r|<0.3 or FC=0.5-2) were highlighted in light green, while stronger correlations were highlighted in deeper green. Results with p<0.05, but FDR >0.1 are highlighted in grey.
IL, interleukin; IFN-γ, interferon gamma; TNF, tumour necrosis factor; ICAM-1, intercellular adhesion molecule 1; IP-10, interferon-gamma induced protein 10; VEGF, vascular endothelial growth factor; sCD40L, soluble CD40 ligand; G-CSF, granulocyte-colony stimulating factor; CCL5, CC motif chemokine ligand 5; TNF-RI, soluble TNF-receptor I; PD-L1, programmed cell death protein ligand 1; TPS, tumor proportion score.